[ET Net News Agency, 11 June 2025] UBS raised the target price for Hansoh Pharma (03692)
to HKD33.3 from HKD24 and maintained the "buy" rating.
The research house said it raises 2025/26/27E EPS 16.2%/17.7%/21.3%, assuming higher
revenue and OPM. (rc)